Search results for " transplantation"

showing 10 items of 1513 documents

Mandibular connective tissue pedicle flaps in implant dentistry: report of three cases.

2007

Abstract An increase in soft tissues and alveolar bone in the anterior mandibular area between the canines is necessary to achieve a good esthetic result. The present article describes a technique for gaining bone volume and soft tissue to cover bone defects that would otherwise compromise the final result of prosthetic implant restoration in the anterior mandible. Three patients with anterior mandibular atrophy caused by loss of the mandibular incisors are presented. Particulate autologous bone grafting, the raising of a pediculate connective tissue flap to increase soft tissue, and implant placement were carried out simultaneously. After 2 years of follow-up, the implants were in good cli…

AdultMaleAlveolar Bone LossGingivaDentistryConnective tissueMandibleEsthetics DentalTransplantation AutologousSurgical FlapsAtrophyOsseointegrationmedicineHumansDental alveolusOrthodonticsDental ImplantsBone TransplantationImplant dentistrybusiness.industryMandibleSoft tissueAlveolar Ridge AugmentationMiddle Agedmedicine.diseaseIncisormedicine.anatomical_structureConnective TissueFemaleImplantOral SurgeryAtrophybusinessBone volumeFollow-Up StudiesThe Journal of oral implantology
researchProduct

Vertical guided bone regeneration with bioabsorbable barriers.

2007

Guided bone regeneration (GBR) is a very useful surgical technique to increase limited alveolar bone for implant placement. The use of non-resorbable barriers is well established; however, bioabsorbable collagen membranes may simplify the surgical technique and make it more predictable.Vertical ridge augmentation was performed on 11 patients at the time of implant placement. The part of the implant out of bone was covered with autogenous bone/graft, and a slow-resorption collagen membrane was placed on top. Gingival tissues were closed with horizontal mattress and interrupted sutures. Second-stage surgery was performed 4 to 6 months later, and healing abutments were placed. The length of th…

AdultMaleBone RegenerationDentistryMandibleOsseointegrationAbsorbable ImplantsMedicineHumansBone regenerationDental alveolusBone Transplantationbusiness.industryDental Implantation EndosseousMandibleMembranes ArtificialVertical DimensionAlveolar Ridge AugmentationAlveolar Ridge AugmentationMiddle AgedAbsorbable ImplantsImplant placementGuided Tissue Regeneration PeriodontalPeriodonticsFemaleImplantCollagenbusinessJournal of periodontology
researchProduct

A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acut…

2013

Unlike cytarabine, cellular entry of Elacytarabine, the elaidic acid ester derivative of cytarabine, is independent of the human equilibrative nucleoside transporter 1 (hENT1). This phase II study tested whether the hENT1 blast expression level can be used as a predictive marker for cytarabine response and if the efficacy of elacytarabine is independent of hENT1 expression. A total of 51 patients with acute myeloid leukemia (AML) induction failure were given elacytarabine-idarubicin as a second induction course. The hENT1 expression level was analyzed prior to first induction and/or prior to treatment with elacytarabine. The overall response rate (ORR) was 41% and the safety profile was man…

AdultMaleCancer ResearchAdolescentPhases of clinical researchGene ExpressionPharmacologyNucleoside transporterEquilibrative nucleoside transporter 1Equilibrative Nucleoside Transporter 1Young AdultBone MarrowAntineoplastic Combined Chemotherapy ProtocolsmedicineIdarubicinHumansAgedPredictive markerbiologyElacytarabinebusiness.industryCytarabineHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyInduction ChemotherapyMiddle AgedLeukemia Myeloid AcuteTreatment OutcomeOncologybiology.proteinCytarabineFemalebusinessIdarubicinmedicine.drugLeukemialymphoma
researchProduct

Pneumonia in Febrile Neutropenic Patients and in Bone Marrow and Blood Stem-Cell Transplant Recipients: Use of High-Resolution Computed Tomography

1999

PURPOSE: To obtain statistical data on the use of high-resolution computed tomography (HRCT) for early detection of pneumonia in febrile neutropenic patients with unknown focus of infection. MATERIALS AND METHODS: One hundred eighty-eight HRCT studies were performed prospectively in 112 neutropenic patients with fever of unknown origin persisting for more than 48 hours despite empiric antibiotic treatment. Fifty-four of these studies were performed in transplant recipients. All patients had normal chest roentgenograms. If pneumonia was detected by HRCT, guided bronchoalveolar lavage was recommended. Evidence of pneumonia on chest roentgenograms during follow-up and micro-organisms detected…

AdultMaleCancer ResearchHigh-resolution computed tomographymedicine.medical_specialtyNeutropeniamedicine.medical_treatmentHematopoietic stem cell transplantationNeutropeniaFever of Unknown OriginPredictive Value of TestsmedicineHumansProspective StudiesFever of unknown originLungAgedBone Marrow TransplantationAged 80 and overmedicine.diagnostic_testbusiness.industryRespiratory diseaseHematopoietic Stem Cell TransplantationPneumoniaMiddle Agedrespiratory systemmedicine.diseaserespiratory tract diseasesSurgeryLeukemia Myeloid AcutePneumoniaBronchoalveolar lavageOncologyFemaleRadiologyTomography X-Ray ComputedComplicationbusinessBronchoalveolar Lavage FluidAlgorithmsJournal of Clinical Oncology
researchProduct

Soft tissue Ewing's sarcoma. Characterization in established cultures and xenografts with evidence of a neuroectodermic phenotype.

1990

This study characterizes the histogenesis of soft tissue Ewing’s sarcoma (StEs) based upon an analysis of three tumors. Long-term cultured cell lines and nude mice xenografts were established from original neoplasms or from their metastases. Histologically they revealed a small round cell pattern without signs of differentiation. Several ultrastructural features of neural type were found; the same were also seen on culture cell lines. Moreover, immunohistochemical study for neural markers revealed the presence of HNK-1, NSE, LIRC-LON 36, S-100 protein, glial fibrillary acidic protein, neurofilaments (70 kilodaltons), and chromogranin; some of these markers were present only in the transplan…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyNeurofilamentAdolescentSynaptophysinMice NudeSoft Tissue NeoplasmsSarcoma EwingBiologyHistogenesisProto-Oncogene Proteins c-mycCytokeratinMiceCD57 AntigensIntermediate Filament ProteinsGlial Fibrillary Acidic ProteinmedicineChromograninsTumor Cells CulturedAnimalsHumansMice Inbred BALB CGlial fibrillary acidic proteinS100 ProteinsEwing's sarcomaChromogranin AMembrane ProteinsNeoplasms Germ Cell and Embryonalmedicine.diseaseAntigens DifferentiationOncologyKaryotypingPhosphopyruvate Hydratasebiology.proteinImmunohistochemistryFemaleSarcomaNeoplasm TransplantationCancer
researchProduct

Cyclosporin- and nifedipine-induced gingival overgrowth in renal transplant patients: correlations with periodontal and pharmacological parameters, a…

1996

The factors associated with cyclosporin A (CsA)- and nifedipine (Nif)-induced gingival overgrowth were investigated in 113 renal transplant recipients receiving CsA alone (Group 1) [n = 61], CsA and Nif (Group 2) [n = 28], or azathioprine (Aza) (Control Group) [n = 24]. Periodontal and pharmacological parameters were assessed for each patient. The patients with a gingival overgrowth index (GOI) score1 were considered responders (R); those with a score/= 1 were non-responders (NR). Gingival overgrowth occurred in 33.7% of the patients in Groups 1 and 2; 60% of the responders were receiving CsA+Nif. In R, no relationship was found between the GOI and the periodontal and pharmacological parame…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentNifedipineAzathioprineGastroenterologyPathology and Forensic MedicinePathogenesisNifedipineHLA AntigensInternal medicineCyclosporin aAzathioprinePrevalencemedicineHumansPeriodontal PocketDental CalculusChildSalivaKidney transplantationKidneyHLA-A AntigensGingival Overgrowthbusiness.industryDental Plaque IndexMiddle AgedCalcium Channel Blockersmedicine.diseaseGingivitisKidney TransplantationTransplantationEndocrinologymedicine.anatomical_structureOtorhinolaryngologyToxicityCyclosporineIrritantsPeriodonticsFemaleDisease SusceptibilityPeriodontal IndexOral SurgerybusinessImmunosuppressive Agentsmedicine.drugJournal of Oral Pathology and Medicine
researchProduct

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

2005

BACKGROUND In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg®), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML). METHODS Patients with CD33-positive AML in first recurrence were entered in 3 open-label, single-arm, Phase II studies. Patients received monotherapy with GO 9 mg/m2 as a 2-hour intravenous infusion in 2 doses separated by 2 weeks. Patients were evaluated for remission, survival, and treatment-emergent adverse events. RESULTS Two hundred seventy-seven patients (median age, 61 yrs) were treated with GO, and 71 patients (26%) achieved remission, which was defined as ≤ 5% blasts in the bone marrow wit…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidMaximum Tolerated DoseGemtuzumab ozogamicinmedicine.medical_treatmentCD33Sialic Acid Binding Ig-like Lectin 3Antigens Differentiation MyelomonocyticHematopoietic stem cell transplantationNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleClinical Trials Phase II as TopicAntigens CDRecurrenceInternal medicinemedicineHumansSingle-Blind MethodSurvival rateAgedAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseGemtuzumabSurgerySurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureAminoglycosidesTreatment OutcomeOncologyEvaluation Studies as TopicFemalebusinessmedicine.drugFollow-Up StudiesCancer
researchProduct

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

2014

Purpose Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown. Patients and Methods In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1)…

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentMedizinDrug resistanceHematopoietic stem cell transplantationMastocytosis SystemicInternal medicinemedicineHumansTransplantation HomologousSystemic mastocytosisChildSurvival rateAgedRetrospective StudiesmastocytosisHematologybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationORIGINAL REPORTSMiddle Agedmedicine.diseaseMast cell leukemia3. Good healthSurvival RateTransplantationSettore MED/15 - MALATTIE DEL SANGUEHaematopoiesisTreatment OutcomeOncologyImmunologyCancer researchFemalebusinesstransplantation
researchProduct

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With…

2012

Purpose This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT). Patients and Methods Overall, 269 patients were randomly assigned to receive bortezomib (1.3 mg/m2 intravenous bolus) or no bortezomib for 1 year, in combination with thalidomide (200 mg per day orally) and dexamethasone (40 mg orally once a day on 4 days once every 3 weeks). Bortezomib was administered on days 1, 4, 8, and 11 with a 10-day rest period (day 12 to day …

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation AutologousGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleSettore MED/01 - Statistica MedicaBortezomib03 medical and health sciences0302 clinical medicineRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAutologous transplantationSurvival rateMultiple myelomaDexamethasoneAgedBortezomibbusiness.industryHazard ratioTranslational research Immune Regulation [ONCOL 3]Middle Agedmedicine.diseaseBoronic AcidsThalidomide3. Good healthSurgeryThalidomideTransplantationTreatment OutcomeOncologyPyrazines030220 oncology & carcinogenesisFemaleMultiple MyelomabusinessStem Cell Transplantation030215 immunologymedicine.drugJournal of Clinical Oncology
researchProduct

Diagnosis and grading of acute graft-versus-host disease in endoscopic biopsy series throughout the upper and lower intestine in patients after allog…

2019

Intestinal graft-versus-host disease (GvHD) is a potentially life-threatening condition after allogenic hematological stem cell transplantation (alloHSCT). Although efforts have been made to determine the best sites for endoscopic biopsies, an approach involving all accessible anatomical regions is lacking. We investigated 22 complete biopsy series, each comprising biopsies from 10 different sites of the upper and lower intestine from 21 patients. The majority of biopsies investigated revealed histological signs of acute GvHD. The highest incidence and most advanced grades of acute GvHD were found in the right colon and terminal ileum. We detected significant correlations between crypt or g…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBiopsyGraft vs Host DiseaseIleumApoptosisHematopoietic stem cell transplantationDiseaseGastroenterologySeverity of Illness Index03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansTransplantation HomologousGrading (tumors)Agedbusiness.industryStomachHematopoietic Stem Cell TransplantationEndoscopyHematologyMiddle Agedmedicine.diseaseTransplantationPatient Outcome Assessmentsurgical procedures operativemedicine.anatomical_structureGraft-versus-host diseaseOncology030220 oncology & carcinogenesisHematologic NeoplasmsFemaleStem cellbusinessImmunosuppressive Agents030215 immunologyLeukemialymphoma
researchProduct